investors Relations



BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Drug Discovery

BenevolentAI has a proven track-record of scientifically validated discoveries. The Benevolent Platform™ powers  a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA.

disease area
target id
chemistry & lead optimization
BEN2293 | atopic dermatitis
BEN8744 | ulcerative colitis
BEN9160 | amyotrophic lateral sclerosis
glioblastoma multiforme
inflammatory bowel diseases
atopic dermatitis
ulcerative colitis
amyotrophic lateral sclerosis
inflammatory bowel diseases
glioblastoma miltiforme
View Full Pipeline

Press Releases

BenevolentAI & Odyssey Combination

Presentations & Webcasts

Corporate Governance

Press Releases
& Events

all press releases→

Latest News

Sep 27, 2022

Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.

Sep 27, 2022

BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.


Sep 8, 2022

Ivan Griffin, BenevolentAI’s COO and Co-Founder, will join this webinar with Oliver Wyman to cover how AI and machine learning can transform drug discovery.

Jun 28, 2022

Join BenevolentAI's CEO, Joanna Shields, at the Morgan Stanley Putting the Tech in Biotech Conference